Efficacy of voriconazole on leishmaniasis by Leishmania major: An in vitro and in vivo study
Objective: To appraise the activity of voriconazole against Leishmania major (L. major) in vitro and its effectiveness on wound regeneration in cutaneous leishmaniasis in BALB/c mice. Methods: The IC50 of voriconazole against promastigotes and intra-macrophage amastigotes of L. major was investigate...
| Published in: | Asian Pacific Journal of Tropical Medicine |
|---|---|
| Main Authors: | , , |
| Format: | Article in Journal/Newspaper |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2018
|
| Subjects: | |
| Online Access: | https://doi.org/10.4103/1995-7645.244516 https://doaj.org/article/25b86b4312e047b1a7a3e91b862f2358 |
| Summary: | Objective: To appraise the activity of voriconazole against Leishmania major (L. major) in vitro and its effectiveness on wound regeneration in cutaneous leishmaniasis in BALB/c mice. Methods: The IC50 of voriconazole against promastigotes and intra-macrophage amastigotes of L. major was investigated in vitro. The in vivo study was performed by treating the L. major infected BALB/c mice. When the wounds appeared in the base of tail, treatment was started by administration of 30 mg/kg voriconazole for 28 consecutive days orally. Results: The IC50 of voriconazole against promastigotes and intra-macrophage amastigotes were 0.74 and 0.89 ģĢ, respectively. Voriconazole decreased lipid peroxidation and IL-6 level. Histopathological findings indicated accelerated healing in the voriconazole treated group compared to other groups. Conclusions: Our results demonstrate that voriconazole can be an option in treating the cutaneous leishmaniasis by L. major. |
|---|